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A 72-year-old man with hypertension, dys-
lipidemia, diabetes mellitus and atrial fibrillation 
underwent coronary angiography due to unstable 
angina in 2012. A two-vessel disease was found 
and percutaneous coronary revascularization was 
performed. Mid left anterior descending (LAD) and 
distal right coronary artery (RCA) were treated 
with 3 × 28 mm and 2.5 × 18 mm bioresorbable 
vascular scaffolds, respectively (Absorb BVS, Ab-
bott Vascular, Santa Clara, CA, USA). Although this 
was probably not the best case for bioresorbable 
scaffold implantation, Absorbs BVS were used due 
to the apparent technical simplicity of these two 
lesions and the hypothetical benefit of bioresorb-
able technology in case of future anastomosis of 
bypass grafts. Pre-dilatation and high pressure 
post-dilatation were performed with non-compliant 
balloons in both cases. The final result was evalu-
ated with optical coherence tomography (OCT), 
which showed a short segment of mild under-
expansion in RCA (minimal scaffold area after post 
dilation 4.01 mm2) and an optimal result in LAD 
(Fig. 1, Panels A-1.1, A-1.2, A-1.3). The patient 
was discharged 4 days later on dual antiplatelet 
therapy, beta-blockers, angiotensin-converting 
enzyme inhibitors and statins.  
Six months later, the patient was readmitted 
due to a new episode of unstable angina. A new 
coronary catheterization showed a restenosis of the 
distal RCA scaffold, without restenosis of LAD BVS 
or any other coronary lesion. BVS restenosis was 
pre-dilated with an AngioSculpt balloon (Angio-
Score, CA, USA); then, a 2.5 × 28 mm everolimus-
eluting stent (Xience, Abbott Laboratories, Abbott 
Park, IL, USA) was implanted. An OCT analysis 
was performed before and after drug-eluting stent 
(DES) implantation and showed that restenosis was 
located at the zone of the initial under-expansion 
(Fig. 1, Panels A-2.1, A-2.2, A-2.3). 
The patient underwent left atrial appendage 
closure and pacemaker implantation in 2014. In 
2017, he was again readmitted to hospital complain-
ing of dyspnea and atypical chest pain. Due to his 
past medical history, he underwent a new coronary 
catheterization in order to discard a new restenosis 
or coronary lesion. There was no evidence of new 
lesions or restenosis after coronary angiography, 
so a new OCT analysis was performed over the 
scaffolded segments of RCA and LAD.  
Bioresorbable vascular scaffold were com-
pletely reabsorbed in both LAD and RCA with 
adequate development of a new neointimal layer. 
A signal-rich layer development was observed in 
LAD, which corresponds to neointima and under-
laying tissue in OCT image (Fig. 1, Panels B-3.1, 
B-3.2, B-3.3). On the other hand, this pattern 
was not seen in RCA because of the previously 
implanted DES. In this case, and thanks to BVS 
bioresorption, RCA looked like a common stented 
artery evaluated by OCT after metallic stent en-
dothelization (Fig. 1, Panels A-3.1, A-3.2, A-3.3).
Absorb BVS was one of the first bioresorbable 
scaffolds to be developed and it was ready for use 
in most European countries in 2012 [1]. The first 
studies showed good long-term outcomes with this 
device [2, 3], but safety has been questioned re-
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cently. In this regard, differing long-term follow-up 
trials suggest that BVS is associated with a higher 
incidence of thrombosis and myocardial infarction 
[4–6]. However, these adverse results may be 
related to an improper implantation technique and 
some technical aspects of the scaffold itself such 
as large profile, thick stent strut, scaffold deforma-
tion during the resorption period, and other issues 
[7]. In this context, intensive research is ongoing 
worldwide to clarify the importance of implanta-
tion technique for long-term results of this scaffold 
in the real world [8]. Nonetheless, there is not 
enough information about BVS bioresorption apart 
from ABSORB studies. BVS bioresorption has only 
been demonstrated in vivo by OCT after long-term 
follow-up in cohort A and B of the ABSORB stud-
ies [9, 10]. In this case, OCT findings after 5-year 
follow-up of  actual patients previously treated with 
Absorb BVS and complicated with early scaffold 
restenosis, only one of them showed full reabsorp-
tion of both BVS.
In summary, fully bioresorption of Absorb BVS 
was found at 5-year follow-up in both scaffolded 
arteries, regardless of in-BVS restenosis. After 
scaffold resorption, an adequate healing process 
with signal-rich development was observed in 
LAD, while this pattern was less evident in RCA 
because of the previously implanted DES. In this 
context, DES implantation is a good therapeutic 
option for BVS restenosis. 
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Figure 1. Coronary angiography and optical coherence tomography (OCT) findings after scaffold implantation. A. Right 
coronary artery (RCA): A-1.1. A severe lesion of distal RCA (red arrow); A-1.2. Result after scaffold implantation; A-1.3. 
Under-expanded Absorb by OCT. A-2.1. A severe in-bioresorbable scaffold implantation (BVS) restenosis in distal 
RCA (red arrow); A-2.2, A-2.3. OCT findings before and after restenosis treatment with drug-eluting stent implanta-
tion. A-3.1, A-3.2, A-3.3. Angiography and OCT findings at 5-year follow-up. B. Left anterior descending (LAD): B-1.1. 
Severe lesion of mid LAD (red arrow); B-1.2. Result after scaffold implantation; B-1.3. Normal position of scaffold by 
OCT. B-2.1, B-2.2, B-2.3. Normal coronary angiography without BVS restenosis in 2013. B-3.1, B-3.2, B-3.3. Angio-
graphy and OCT findings at 5-year follow-up.
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